[{"id":"a3758200-2675-4c3a-9e8c-8a19c87396ef","acronym":"","url":"https://clinicaltrials.gov/study/NCT04230265","created_at":"2023-08-14T10:11:02.629Z","updated_at":"2025-02-25T15:43:50.590Z","phase":"Phase 1","brief_title":"Phase 1 Study of UniCAR02-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies","source_id_and_acronym":"NCT04230265","lead_sponsor":"AvenCell Europe GmbH","biomarkers":" IL3RA","pipe":" | ","alterations":" CD123 positive","tags":["IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • AVC-101"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 01/28/2020","start_date":" 01/28/2020","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2025-02-11"}]